GILLIS JONATHAN 4

What Happened
Jonathan Gillis, MapLight Therapeutics’ Chief Accounting and Principal Accounting Officer (CAAO/PAO), sold a total of 69,835 shares in multiple open-market transactions on April 27–28, 2026 for aggregate proceeds of $2,087,688. The sales were reported as Rule 10b5-1 plan trades and were reported on a Form 4 filed April 29, 2026. Individual transactions reported:

• 7,914 shares at $28.94 — $229,031 (sold across prices $28.27–$29.25)
• 29,623 shares at $29.60 — $876,841 (sold across prices $29.27–$30.25)
• 14,363 shares at $30.46 — $437,497 (sold across prices $30.27–$30.64)
• 17,235 shares at $30.33 — $522,738 (sold across prices $29.755–$30.71)
• 700 shares at $30.83 — $21,581 (sold across prices $30.81–$30.86)

Key Details

• Transaction type: S = Sale (open-market / private sale) under a Rule 10b5-1 trading plan (plan adopted Dec 26, 2025).
• Dates: April 27 and April 28, 2026; Form 4 filed April 29, 2026 (appears timely).
• Total shares sold: 69,835 for total proceeds of $2,087,688 (reported as weighted-average prices with ranges per footnotes).
• Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
• Footnotes: Several weighted-average price footnotes list the price ranges for the multiple executions; the filer offers to provide a breakdown of shares sold at each price on request.

Context

• Sales executed under a 10b5-1 plan are pre-arranged and typically indicate planned disposition rather than ad hoc trading; they do not by themselves signal the filer’s current view on the company.
• For retail investors, purchases generally carry more informational weight than routine, planned insider sales—but monitoring insider activity over time can provide additional context.